Sofosbuvir as treatment against dengue?
Dengvaxia® (CTD-TDV), the only licensed tetravalent dengue vaccine by Sanofi Pasteur, was made available since 2015. However, administration of CTD-TDV, in general, has not received the prequalification recommendation from the World Health Organization. Having a universal antidengue agent for treatm...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Published: |
Wiley
2017
|
| Subjects: |
| _version_ | 1796961557506162688 |
|---|---|
| author | Gan, Chye Sheng Lim, See Khai Chee, Chin Fei Yusof, Rohana Heh, Choon Han |
| author_facet | Gan, Chye Sheng Lim, See Khai Chee, Chin Fei Yusof, Rohana Heh, Choon Han |
| author_sort | Gan, Chye Sheng |
| collection | UM |
| description | Dengvaxia® (CTD-TDV), the only licensed tetravalent dengue vaccine by Sanofi Pasteur, was made available since 2015. However, administration of CTD-TDV, in general, has not received the prequalification recommendation from the World Health Organization. Having a universal antidengue agent for treatment will therefore beneficial. Accordingly, the development of nucleoside inhibitors specific to dengue viral polymerase that perturb dengue infection has been studied by many. Alternatively, we have used a marketed anti-HCV prodrug sofosbuvir to study its in silico and in vitro effects against dengue. As a result, the active metabolite of sofosbuvir (GS-461203) was predicted to bind to the catalytic motif (Gly-Asp-Asp) of dengue viral polymerase with binding affinity of −6.9 kcal/mol. Furthermore, sofosbuvir demonstrated excellent in vitro viral inhibition with an EC90 of 0.4 μm. In addition, this study demonstrated the requirement of specific liver enzymes to activate the prodrug into GS-461203 to exert its antidengue potential. All in all, sofosbuvir should be subjected to in-depth studies to provide information of its efficacy toward dengue and its lead potential as DENV polymerase inhibitor in human subjects. In conclusion, we have expended the potential of the clinically available drug sofosbuvir as treatment for dengue. |
| first_indexed | 2024-03-06T05:55:53Z |
| format | Article |
| id | um.eprints-22051 |
| institution | Universiti Malaya |
| last_indexed | 2024-03-06T05:55:53Z |
| publishDate | 2017 |
| publisher | Wiley |
| record_format | dspace |
| spelling | um.eprints-220512019-08-26T02:23:21Z http://eprints.um.edu.my/22051/ Sofosbuvir as treatment against dengue? Gan, Chye Sheng Lim, See Khai Chee, Chin Fei Yusof, Rohana Heh, Choon Han R Medicine Dengvaxia® (CTD-TDV), the only licensed tetravalent dengue vaccine by Sanofi Pasteur, was made available since 2015. However, administration of CTD-TDV, in general, has not received the prequalification recommendation from the World Health Organization. Having a universal antidengue agent for treatment will therefore beneficial. Accordingly, the development of nucleoside inhibitors specific to dengue viral polymerase that perturb dengue infection has been studied by many. Alternatively, we have used a marketed anti-HCV prodrug sofosbuvir to study its in silico and in vitro effects against dengue. As a result, the active metabolite of sofosbuvir (GS-461203) was predicted to bind to the catalytic motif (Gly-Asp-Asp) of dengue viral polymerase with binding affinity of −6.9 kcal/mol. Furthermore, sofosbuvir demonstrated excellent in vitro viral inhibition with an EC90 of 0.4 μm. In addition, this study demonstrated the requirement of specific liver enzymes to activate the prodrug into GS-461203 to exert its antidengue potential. All in all, sofosbuvir should be subjected to in-depth studies to provide information of its efficacy toward dengue and its lead potential as DENV polymerase inhibitor in human subjects. In conclusion, we have expended the potential of the clinically available drug sofosbuvir as treatment for dengue. Wiley 2017 Article PeerReviewed Gan, Chye Sheng and Lim, See Khai and Chee, Chin Fei and Yusof, Rohana and Heh, Choon Han (2017) Sofosbuvir as treatment against dengue? Chemical Biology & Drug Design, 91 (2). pp. 448-455. ISSN 1747-0277, DOI https://doi.org/10.1111/cbdd.13091 <https://doi.org/10.1111/cbdd.13091>. https://doi.org/10.1111/cbdd.13091 doi:10.1111/cbdd.13091 |
| spellingShingle | R Medicine Gan, Chye Sheng Lim, See Khai Chee, Chin Fei Yusof, Rohana Heh, Choon Han Sofosbuvir as treatment against dengue? |
| title | Sofosbuvir as treatment against dengue? |
| title_full | Sofosbuvir as treatment against dengue? |
| title_fullStr | Sofosbuvir as treatment against dengue? |
| title_full_unstemmed | Sofosbuvir as treatment against dengue? |
| title_short | Sofosbuvir as treatment against dengue? |
| title_sort | sofosbuvir as treatment against dengue |
| topic | R Medicine |
| work_keys_str_mv | AT ganchyesheng sofosbuvirastreatmentagainstdengue AT limseekhai sofosbuvirastreatmentagainstdengue AT cheechinfei sofosbuvirastreatmentagainstdengue AT yusofrohana sofosbuvirastreatmentagainstdengue AT hehchoonhan sofosbuvirastreatmentagainstdengue |